Michael Forbes, CEO of Adastra, claimed in his First press release: “Hurt reduction is often a critically critical and mainstream subject, and we are staying within the forefront of drug restrictions throughout the board.”“We will Assess how the commercialization of the substance matches in with our enterprise product at Adastra in an effort